MTOR and neoplasm with perivascular epithelioid cell differentiation: Also, when analyzing only patients with malignant PEComa, we found no significant associations for combined cPFS (Supplementary Table S12; Supplementary Fig. S9), as well as no difference in combined cPFS between patients treated with mTOR inhibitors considered separately, ICI, chemotherapy, and other treatments (P = 0.93, log-rank; Supplementary Fig. S10).